Takeda to Acquire Adaptate Biotherapeutics to Expand γδ T Cell Engager Platform for Solid Tumors

Gilead Sciences to Acquire Tubulis (Up to $5.0B) to Expand ADC Oncology Pipeline

April 7, 2026

Biotechnology

Gilead Sciences entered into a definitive agreement to acquire Tubulis, a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront in cash plus up to $1.85 billion in contingent milestone payments. Following completion, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation.

Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company

April 7, 2025

Biotechnology

Epsilogen Ltd has completed the acquisition of Boston-based TigaTx, Inc., making TigaTx a wholly owned subsidiary. The deal combines TigaTx's engineered IgA antibody assets with Epsilogen's IgE capabilities to build a pan-isotype oncology antibody company and broaden the combined clinical-stage pipeline.

Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

March 6, 2023

Healthcare Services

Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.

Takeda Pharmaceutical to Acquire GammaDelta Therapeutics

October 27, 2021

Biotechnology

Takeda exercised its option to acquire GammaDelta Therapeutics Limited, gaining its allogeneic gamma-delta (γδ) T cell therapy platforms and early-stage cell therapy programs. The acquisition is expected to be finalized in Q1 of Takeda’s fiscal year 2022, subject to antitrust review (including HSR).

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

March 9, 2021

Biotechnology

Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.